IQM-QUANTUM-COMPUTERS
7.4.2022 17:23:05 CEST | Business Wire | Press release
IQM Quantum Computers , Hebrew University of Jerusalem and Bar-Ilan University have started a research cooperation on quantum technologies, with IQM providing commercial-grade quantum-computing hardware components to both universities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220407005722/en/
IQM, the Pan-European leader in quantum computers, Hebrew University of Jerusalem and Bar-Ilan University, among the leading universities in the world, announced today cooperation in quantum computing focused on research, exchange of know-how and quantum hardware.
The purpose of the cooperation is to provide the researchers at the Hebrew University of Jerusalem (in the group led by Professor Nadav Katz within its Physics Department and Quantum Information Science Center) and Bar-Ilan University (in the group led by Professor Michael Stern, of the Department of Physics) commercial-grade quantum-computing hardware developed by IQM. Researchers in these groups will conduct experiments using the IQM hardware and further advance scientific development.
The initiative also includes testing IQM’s qubit technology and conducting experiments based on its hardware. This long-term cooperation will result in significant scientific breakthroughs, several academic contributions and new product innovations. This is in line with IQM’s chosen strategy of providing its customers and partners direct access to hardware components.
Speaking about this announcement, Dr. Juha Vartiainen, COO and cofounder of IQM, said, “We are very happy to be working with both the Hebrew University of Jerusalem and Bar-Ilan University and look forward to a fruitful, long-term scientific and commercial cooperation. This announcement aligns well with our strategy to provide commercial-grade quantum-computing hardware to global research groups.”
“This cooperation is also a significant milestone for our cooperation with the world-class quantum ecosystem in Israel. As quantum computers develop further, the know-how developed in Israel—for example, around machine learning and quantum software—is going to become more critical in the future,” added Juha.
In the future, all parties also aim to extend the collaboration toward building full-stack quantum computers for scientific and commercial purposes in Israel.
“We are excited about this new collaboration with IQM and have already measured several consistently high-coherence IQM devices in our lab in Israel. This is just the beginning of a productive and fruitful joint venture,” shared Prof. Nadav Katz, director of HUJI’s Quantum Information Science Center.
Highly coherent controlled oscillations of IQM’s qubits measured in Israel (HUJI).
“We are proud to take part in a study that places Israel and its universities at the forefront of the global effort to develop quantum computers. The road is still long, but I believe that we at Bar-Ilan, together with our partners at the Hebrew University, will succeed in achieving groundbreaking results,” said Prof. Michael Stern.
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM provides on-premises quantum computers for supercomputing data centers and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer, which will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has over 160 employees with offices in Paris, Bilbao, Munich and Espoo.
For more information: www.meetiqm.com
Recent IQM announcements:
- BioNTech Chief Operating Officer Dr. Sierk Poetting is to steer IQM global expansion as chairman .
- IQM continues its European expansion; the new French subsidiary will focus on IQM’s co-design customers in aviation, space and cybersecurity.
- IQM has opened its exclusive quantum fabrication facility in Finland.
- IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
- IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.
Registered office:
IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland
About the Hebrew University of Jerusalem:
The Hebrew University of Jerusalem (HUJI) is Israel’s leading academic and research institution, serving over 25,000 students from some 80 countries on 6 campuses. Founded in 1918 by luminaries including Albert Einstein, Chaim Weizmann, Sigmund Freud and Martin Buber, HUJI is ranked in the top echelon of the world’s leading universities. To date, HU faculty and alumni have won 8 Nobel Prizes, 1 Fields Medal and 1 Abel Prize—a proud tradition of innovation and excellence.
About Bar-Ilan University:
Bar-Ilan University, founded in 1955, is one of Israel’s leading institutions of higher education, uniquely combining cutting-edge scientific research with education steeped in Jewish values and social responsibility. Having grown from 70 students to close to 20,500 students, its milestone achievements in the sciences and humanities and all fields of human endeavor have made an indelible imprint on the landscape of the State of Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
